O-1A Guide
O-1A Judging Criterion: A biotech CEO's Guide for September 2023
This guide covers the latest strategies and evidence requirements. Learn what changed and how to position your case.
What the judging criterion requires for O-1A petitions
The judging criterion at 8 C.F.R. § 214.2(o)(3)(iii)(D) requires evidence that the beneficiary has participated, either individually or on a panel, as a judge of the work of others in the same or an allied field of specialization for which classification is sought. For an O-1A petition based on extraordinary ability in the sciences or business, this criterion is satisfied by evidence of formal evaluation roles in which the beneficiary applies expert knowledge to assess the work of others—not merely that the beneficiary reviews and evaluates work in the ordinary course of their employment, but that they have been formally recognized and appointed to judging roles that reflect the field's assessment of the beneficiary's expertise as evaluatively significant.
For biotech industry executives—CEOs, founders, and senior leaders with scientific backgrounds who occupy roles at the intersection of business and technical sciences—the judging criterion can be satisfied through several mechanisms: serving as a reviewer for peer-reviewed journals in relevant biotech or life science disciplines, participating as a grant reviewer on NIH study sections or equivalent panels at the National Science Foundation, serving on scientific advisory boards of other companies where the role involves formal evaluation of technical programs, or participating as a judge in business plan competitions, innovation awards, or pitch competitions with defined selection criteria in the biotech or life science sectors.
The regulatory language is broad enough to encompass both scientific judging roles (journal peer review, grant review) and business judging roles (investment committee participation in a formal capacity, serving on selection committees for industry awards), provided the judging is in the same or an allied field as the extraordinary ability classification being sought. For a biotech CEO seeking O-1A classification in business or sciences, both the scientific technical review and the business evaluation components of their professional activity can generate judging criterion evidence. The petition strategy should identify the most credible and well-documented judging roles and present them with clear evidence of the formal appointment or selection to the judging role.
Peer review roles that satisfy the criterion in biotech
Journal peer review is the most straightforward form of judging criterion evidence for biotech executives with scientific backgrounds, and it is routinely accepted by USCIS when properly documented. Scientific journals in the life sciences—including Nature Biotechnology, Cell, Science, PNAS, Journal of Biological Chemistry, Molecular Cell, Cancer Cell, Nature Medicine, and equivalent peer-reviewed publications—regularly invite researchers and industry scientists with domain expertise to review submitted manuscripts. A biotech CEO who has published in the field and has a documented scientific background will typically receive peer review invitations from journals in their area of expertise, and these invitations should be systematically documented with the invitation correspondence and review confirmation.
The documentation for journal peer review should include: invitation emails from the journal editor or editorial office specifying that the beneficiary has been selected to review a manuscript in the beneficiary's area of expertise, the beneficiary's acceptance of the invitation, and any written acknowledgment from the journal of the review's completion. Many journals also publish annual reviewer acknowledgments in print or online, and these acknowledgments—which list peer reviewers by name—serve as independent verification that the review occurred. The petition should also include evidence of the journal's standing: impact factor, scope of readership, and expert letters that explain the journal's reputation within the relevant field.
For biotech executives whose career has transitioned primarily from laboratory research to executive leadership, peer review invitations may have declined from earlier career highs as the executive has moved away from active bench research. In these cases, the petition strategy may need to supplement scientific journal peer review with other forms of judging that better reflect the beneficiary's current professional activity—particularly advisory board roles, grant review panel service, and participation in formal evaluation processes in the biotech industry context that are appropriate for executive-level professionals who maintain scientific expertise but exercise it in executive rather than laboratory roles.
NIH study sections and federal grant review panels
NIH study sections are peer review panels that evaluate grant applications submitted to the National Institutes of Health, and service on a study section is among the most prestigious forms of judging criterion evidence available in the biomedical sciences. Study section members are selected by the NIH Center for Scientific Review based on their expertise in the relevant scientific area, and serving as a permanent or ad hoc member of a study section reflects NIH's assessment that the beneficiary has the expertise necessary to evaluate research proposals in highly competitive funding programs. The appointment letter from NIH, documentation of the specific study section, and any online rosters published by the Center for Scientific Review all provide strong documentation for this criterion.
NSF review panels perform a similar function for basic research across scientific disciplines, including bioengineering, materials science, chemistry, and biology, and service on NSF review panels similarly reflects the recognition of the beneficiary's expertise by a federal scientific agency. DARPA program managers and program participants in ARPA-type agencies are another category of formal scientific evaluation that can satisfy the judging criterion when the role involves formal evaluation of proposals submitted by others in competition for program funding. Documentation for these roles should include the formal appointment or selection communication and any available public information about the panel's composition and scope.
Biotech CEOs whose companies have received significant NIH SBIR/STTR funding, and who have subsequently served on review panels for those same programs, have a particularly strong narrative for the judging criterion because their appointment to the review panel reflects NIH's recognition that their experience as both a scientific researcher and a biotech executive makes them qualified to evaluate the scientific and commercial feasibility of proposals from other early-stage companies. This kind of role-bridging between scientific and commercial expertise is characteristic of extraordinary biotech executives and can be documented with both the formal appointment records and expert letters from NIH program officers or senior reviewers who can explain the significance of the panel appointment.
Scientific advisory board membership as judging criterion evidence
Scientific advisory board (SAB) membership is a form of judging that is particularly common in the biotech industry and is well-suited to O-1A petitions for biotech executives. An SAB member is formally appointed by an organization to evaluate its scientific programs, assess the validity of its research approach, and provide recommendations about the direction of its scientific strategy. This is formally a judging function—the SAB member applies expert knowledge to assess the work of others—performed in a recognized professional context that USCIS can evaluate as evidence of the field's recognition of the beneficiary's expertise.
The strength of SAB membership as judging criterion evidence depends on the nature of the organization and the formality of the membership. SAB membership at a venture-backed biotech company with a documented scientific program, where the membership was conferred through a formal appointment process and involves regular scientific review activities, is more credible evidence than advisory board membership that involves only informal consultation or that was established primarily to generate immigration evidence rather than to serve a genuine organizational function. The petition should document the appointment process, the scope of the SAB member's responsibilities, and the organization's scientific reputation, ideally with letters from the company's scientific leadership that describe specifically how the SAB member's evaluations have contributed to the company's scientific decision-making.
Multiple SAB memberships at different organizations in the biotech or life science sectors collectively demonstrate a pattern of recognition by multiple independent organizations that the beneficiary's expertise is valuable for evaluating scientific programs—which is precisely the kind of external, independent recognition that the judging criterion rewards. Expert letters from CEOs or chief scientific officers at the organizations where the beneficiary serves on SABs can describe the evaluation process, the beneficiary's role, and why the beneficiary was specifically selected for the advisory role based on their exceptional expertise and standing in the field.
Business plan competitions, pitch judging, and industry award panels
Biotech executives with both scientific and business expertise are frequently invited to serve as judges in business plan competitions, startup pitch events, and industry award programs that evaluate both the scientific validity and the commercial potential of biotech ventures. Programs such as the JLABS QUICKfire Challenge, MassChallenge Health, IndieBio Demo Day, BIO International Convention pitch competitions, and equivalent events with recognized standing in the biotech venture community conduct formal judging processes in which the beneficiary is selected to evaluate other teams or companies against defined criteria. Participation as a judge in these events satisfies the judging criterion when the events have documented reputations and the beneficiary's role as a judge—rather than a participant or observer—is clearly established.
Industry award programs that involve formal expert evaluation—such as the Fierce Innovation Awards, BIO Innovation Award, and equivalent programs sponsored by recognized biotechnology industry organizations—provide judging evidence when the beneficiary serves on the selection committee rather than receiving the award. The documentation should distinguish clearly between award receipt (which is evidence for the awards criterion) and judging participation (which is evidence for the judging criterion), because confusing the two evidence types can create credibility problems with USCIS adjudicators who may question why evidence submitted for one criterion appears more relevant to another.
For biotech executives who have served as venture capital fund reviewers—participating formally in the evaluation of investment opportunities on behalf of a VC fund or corporate venture program—this investment evaluation activity may satisfy the judging criterion if it is structured as a formal evaluation role with documented responsibilities and is in the same field as the classification sought. VC portfolio review is a form of evaluating the work of others (the management teams and scientific programs of portfolio candidates) in an allied field of specialization, and expert letters from managing partners or fund directors who can describe the formal evaluation process and the beneficiary's role in it help USCIS understand why the activity satisfies the judging criterion's requirements.
Integrating the judging criterion into a complete biotech CEO petition
The judging criterion is typically one of three to five criteria in a complete O-1A petition for a biotech CEO, and its strongest presentation is as part of a coherent narrative that connects the beneficiary's scientific expertise, business achievements, and external recognition into a unified picture of extraordinary ability at the top of the biotech field. The cover letter should explain why the judging roles reflect the field's recognition of the beneficiary's expertise rather than routine professional activity: that the beneficiary was selected from among many potential reviewers because their specific combination of scientific and business knowledge made them particularly qualified to evaluate the work of others in the biotech industry context.
For biotech CEOs whose primary claim to extraordinary ability is in the business domain—where company achievements, capital raised, revenue generated, and valuation milestones provide the primary evidence of extraordinary achievement—the judging criterion contributes evidence of a different type: external recognition by other organizations of the beneficiary's expertise, as distinct from the beneficiary's own company's performance. A petition that shows a biotech CEO who has built a successful company (achievement evidence) and who has been repeatedly selected by independent organizations to evaluate the scientific and commercial programs of others (recognition evidence) presents a more complete picture of extraordinary ability than achievement evidence alone.
Documentation for the judging criterion in a biotech CEO petition should be organized as a self-contained criterion evidence package: the primary documents establishing each judging role (appointment letters, correspondence, panel rosters), accompanied by documentation of the evaluating organization's reputation and standing, and supported by one or two expert letters from figures in the biotech field who can explain the significance of the specific judging roles. The expert letters should address specifically why those judging roles reflect recognition of extraordinary ability rather than ordinary professional consultation, and should do so by reference to the beneficiary's specific credentials and the standing of the organizations that selected the beneficiary for evaluation roles.